Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo Controlled Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

NCT07218575 is registered in ClinicalTrials.gov with Boston Children's Hospital as lead sponsor.

NCT NCT07218575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07218575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo Controlled Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
Lead sponsor
Boston Children's Hospital
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 30, 2030
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bannayan riley ruvalcaba syndrome, bannayan zonana syndrome, cerebellum dysplastic gangliocytoma, cowden's disease, cowden's syndrome, lhermitte-duclos disease, myhre riley smith syndrome, pten hamartoma tumor syndrome, riley smith syndrome